Actively Recruiting
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
Led by David Wilson · Updated on 2025-04-17
102
Participants Needed
1
Research Sites
290 weeks
Total Duration
On this page
Sponsors
D
David Wilson
Lead Sponsor
R
Rio pharmaceuticals Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).
CONDITIONS
Official Title
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 40-75 years
- Age-appropriate body mass index (BMI)
- Ability to provide written informed consent or have a legal guardian provide consent
- No obvious physical disorders
- Suitable radial, ulnar, or brachial artery for catheterization
- Non-smoker and not using over-the-counter nicotine cessation products
- No central nervous system prescription drugs for at least three weeks
- For some cohorts: must have a study partner who spends at least 5 hours per week with participant
- For some cohorts: recent (within 6 months) Mini-Mental Exam clinical scores available
You will not qualify if you...
- Unable to provide informed consent and no legal representative to provide surrogate consent
- Inadequate arterial access
- Recent receipt of radioisotope within 5 half-lives before imaging
- More than 3 PET scans with [18F]RP-115 within one year
- Contraindications to MRI such as pacemaker, metallic implant, or severe claustrophobia
- Pregnant women
- Breastfeeding women
- Any medical condition or circumstance that may affect data reliability or study completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China Basin, UCSF
San Francisco, California, United States, 94107
Actively Recruiting
Research Team
D
David Wilson, MD, PhD
CONTACT
H
Henry Vanbrocklin, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here